Compare GCBC & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GCBC | CABA |
|---|---|---|
| Founded | 1889 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.8M | 319.6M |
| IPO Year | 1998 | 2019 |
| Metric | GCBC | CABA |
|---|---|---|
| Price | $22.30 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 8.6K | ★ 2.8M |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 26.21 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,117,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.66 | ★ N/A |
| Revenue Growth | ★ 11.06 | N/A |
| 52 Week Low | $20.00 | $0.99 |
| 52 Week High | $26.21 | $3.78 |
| Indicator | GCBC | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 56.08 |
| Support Level | $21.39 | $2.11 |
| Resistance Level | $23.48 | $3.34 |
| Average True Range (ATR) | 0.83 | 0.30 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 19.70 | 43.07 |
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.